A study from European Radiology evaluated the prognostic value of the extracellular volume (ECV) fraction determined by single- and dual-energy CT in patients with stage IV pancreatic ductal adenocarcinoma undergoing chemotherapy. Only the ECV fraction calculated in dual-energy CT may be considered an independent predictor of survival outcomes in these patients.